A Pharmacokinetic Study of BMS-582664 in Subjects with Advanced Solid Tumor Malignancies and Normal Hepatic Function or Hepatocellular Carcinoma with Impaired Hepatic Function.

Trial Profile

A Pharmacokinetic Study of BMS-582664 in Subjects with Advanced Solid Tumor Malignancies and Normal Hepatic Function or Hepatocellular Carcinoma with Impaired Hepatic Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 May 2011

At a glance

  • Drugs Brivanib alaninate (Primary)
  • Indications Liver cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 03 May 2011 Actual end date (1 Jun 2010) added as reported by ClinicalTrials.gov.
    • 03 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top